HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

Back

ESC2025 Premium Access

HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

Session: Therapeutic advances in amyloid cardiomyopathy

Topic: Pharmacotherapy

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

81 presentations

20 followers

5 more presentations in this session

Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy

Speaker: Doctor M. Grogan (Rochester, US)

Echocardiographic assessments of ventricular function and cardiac structure with ALXN2220, an ATTR depleter: analysis from the open-label extension of study NI006-101

Speaker: Doctor F. Aus Dem Siepen (Heidelberg, DE)

Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy

Speaker: Doctor B. Forst (Phoenix, US)

RNA interference therapy in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Speaker: Mr G. Arrighini (Bologna, IT)

The UNOS experience on heart transplantation for amyloid cardiomyopathy

Speaker: Associate Professor A. Briasoulis (Athens, GR)

Access the full session

Therapeutic advances in amyloid cardiomyopathy

Speakers: Doctor P. Garcia-Pavia, Doctor M. Grogan, Doctor F. Aus Dem Siepen, Doctor B. Forst, Mr G. Arrighini...

Access

Video

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources